NeOnc Technologies
Woodland Hills
About NeOnc Technologies
NEONC Technologies is an early-stage cancer biotechnology company focused initially on intranasal (delivery through the nose) inhalation and other nontraditional delivery of a novel, highly purified form of monoterpenes (oils from fruits & plants), alone or with other chemotherapeutic (cancer treatment chemicals) agents. It will initially be used in clinical research for first-line treatment of malignant brain cancer (gliomas) and other aggressive brain cancers, and later for the treatment of lung cancer. NTI was incorporated in the State of Delaware in 2008. The Company has assembled a highly qualified management team and board of directors. NTI is developing several proprietary molecules for clinical research, some of which have demonstrated significant activity (positive results) in laboratory tests; NTI is accordingly building a portfolio of intellectual property around this research. In addition, the company has reached an agreement with a manufacturer of active pharmaceutical ingredients for the development and production of proprietary monoterpenes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $99.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:NTHI
- Website: neonc.com
- Phone: 818-971-5100
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/neonc-technologies-51722 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.